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Abstract
It is well known that the RAS (renin–angiotensin system) plays a key role in the modulation of many functions in the
body. AngII (angiotensin II) acting on AT1R (type 1 AngII receptor) has a central role in mediating most of the actions
of the RAS. However, over the past 10 years, several studies have presented evidence for the existence of a new
arm of the RAS, namely the ACE (angiotensin-converting enzyme) 2/Ang-(1–7) [angiotensin-(1–7)]/Mas axis.
Ang-(1–7) can be produced from AngI or AngII via endo- or carboxy-peptidases respectively. ACE2 appears to play a
central role in Ang-(1–7) formation. As described for AngII, Ang-(1–7) also has a broad range of effects in different
organs and tissues which goes beyond its initially described cardiovascular and renal actions. Those effects are
mediated by Mas and can counter-regulate most of the deleterious effects of AngII. The interaction Ang-(1–7)/Mas
regulates different signalling pathways, such as PI3K (phosphoinositide 3-kinase)/AKT and ERK (extracellular-
signal-regulated kinase) pathways and involves downstream effectors such as NO, FOXO1 (forkhead box O1) and
COX-2 (cyclo-oxygenase-2). Through these mechanisms, Ang-(1–7) is able to improve pathological conditions
including fibrosis and inflammation in organs such as lungs, liver and kidney. In addition, this heptapeptide has
positive effects on metabolism, increasing the glucose uptake and lipolysis while decreasing insulin resistance and
dyslipidaemia. Ang-(1–7) is also able to improve cerebroprotection against ischaemic stroke, besides its effects on
learning and memory. The reproductive system can also be affected by Ang-(1–7) treatment, with enhanced
ovulation, spermatogenesis and sexual steroids synthesis. Finally, Ang-(1–7) is considered a potential anti-cancer
treatment since it is able to inhibit cell proliferation and angiogenesis. Thus the ACE2/Ang-(1–7)/Mas pathway
seems to be involved in many physiological and pathophysiological processes in several systems and organs
especially by opposing the detrimental effects of inappropriate overactivation of the ACE/AngII/AT1R
axis.
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INTRODUCTION
The textbook-like view of the RAS (renin–angiotensin system)
as a linear limited proteolysis pathway toward the production of
a single active end product, AngII (angiotensin II), has changed
dramatically over the past 10 years with the identification of novel
components [ACE (angiotensin-converting enzyme) 2, Mas and
renin/pro-renin receptor] and actions of this system [1–6]. A
major shift in our understanding of the RAS was the proposition
Abbreviations: ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AIA, antigen-induced arthritis; Ang-(1–7), angiotensin-(1–7); Ang-(1–9), angiotensin-(1–9); AngI etc.,
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CTGF, connective tissue growth factor; ERK, extracellular-signal-regulated kinase; FOXO1, forkhead box O1; GnRH, gonadotropin-releasing hormone; HAEC, human aortic endothelial
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Correspondence: Dr Robson A.S. Santos (email santos@icb.ufmg.br or robsonsant@gmail.com).
of the concept of the RAS as a dual axis system: one axis repres-
ented by ACE/AngII/AT1R (type 1 AngII receptor) and the other
by ACE2/Ang-(1–7) [angiotensin-(1–7)]/Mas [7,8]. The identi-
fication of the renin/pro-renin receptor [4] and its physiological
actions, which go beyond its role in the RAS [9], and more re-
cently of the other ACE2 product Ang-(1–9) [angiotensin-(1–9)]
as a biologically active member of the RAS [10,11], suggest
that we are still far from understanding the complexity of this
fascinating system.
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Figure 1 Simplified view of the different pathways of Ang-(1–7) formation and the receptors for Ang-(1–7) and AngII
The starting point in the canonical and non-canonical en-
zymatic pathways of the RAS is the glycoprotein AGT (an-
giotensinogen), which is produced and secreted into the circu-
lation by the liver. Most organs, including the brain, vasculature,
kidney, heart, and lungs, can also produce AGT. The limited pro-
teolysis cascade starts with renin, which plays a central role in
the formation of the inactive decapeptide AngI by cleavage of
AGT. AngI (angiotensin I) can be cleaved by ACE or chymase to
form the octapeptide AngII, and by many other peptidases, espe-
cially PEP (prolyl-endopeptidase), NEP (neutral endopeptidase)
and TOP (thymet oligopeptidase), which can generate Ang-(1–
7) by the cleavage of its Pro7-Phe8 bond. Ang-(1–7) can also
be formed by hydrolysis of AngII via ACE2 [12]. Furthermore,
this heptapeptide can be generated via the hydrolysis of AngI by
ACE2 to form Ang-(1–9), which is subsequently cleaved by NEP
or ACE [13]. However, it is important to stress that this pathway
seems to be catalytically less efficient than the ones mentioned
above [13]. A simplified view of the enzymatic pathways involved
in the formation of Ang-(1–7) is shown in Figure 1.
Accumulating evidence suggests that a balance between the
activation of the ACE/AngII/AT1R axis and the ACE2/Ang-(1–
7)/Mas receptor axis plays an important role in the function of
different organs and systems and that an imbalance in these op-
posing pathways toward the ACE/AngII/AT1R axis predispose
to cardiovascular diseases and other disorders. Several recent re-
views have focused on the cardiovascular and renal actions of
the novel axis of the RAS and its implication in cardiovascular
and renal diseases [6,14–16]. However, this axis has pleiotropic
effects going far beyond its cardio-renal and vascular actions
(Figure 2). In the present paper, we aim to briefly review some
recent aspects related to the non-classical actions of ACE2/Ang-
(1–7)/Mas, especially Ang-(1–7).
GLUCOSE AND LIPID METABOLISM
Both, the pancreas [17,18] and adipose tissue [19], contain RAS
components and this local RAS is highly regulated by food in-
take. Although a high-sugar diet increases the expression levels
of AGT, ACE and AT1R in the pancreas [20], a diet rich in fat
or sugar increases the concentration of ACE2 and Ang-(1–7) in
adipose tissue [21,22]. The RAS is currently being considered as
a potential target for the treatment of the metabolic syndrome,
a disorder characterized by the association of obesity, insulin
resistance, hypertension, diabetes, hyperinsulinaemia and dys-
lipidaemia [23,24].
The observation that insulin resistance is frequently associated
with cardiovascular impairment has drawn the attention of the
scientific community to the possible interplay between the RAS
and insulin. The possibility of such a relationship was prompted
by clinical trials [25–28] and experimental studies [20,29–35]
in which the overall observation was an improvement in hyper-
glycaemia either by inhibiting the ACE/AngII/AT1R axis or by ac-
tivating the ACE2/Ang-(1–7)/Mas axis. These observations also
suggest that, together with bradykinin [36,37], Ang-(1–7) could
have an important anti-hyperglycaemic effect, whereas AngII acts
in the opposite way. Indeed, there are a number of publications
reporting that Ang-(1–7) prevents the metabolic syndrome, in-
creases glucose uptake and protects cells against the oxidative
stress that can induce insulin resistance [31,34,35] (Figure 2B).
The events behind the positive regulation of insulin by Ang-
(1–7) are now being revealed. Ang-(1–7) and insulin have some
common downstream signalling effectors in HAECs (human aor-
tic endothelial cells) [38] and in the rat heart [39] (Figure 2A).
By using Western-blot-based techniques to interrogate Ang-(1–7)
signalling, it has been reported that Ang-(1–7) phosphorylates the
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Figure 2 Main non-cardiovascular effects of Ang-(1–7) via Mas in different tissues and processes
(A) Signalling molecules involved in the action of Ang-(1–7). The molecules in green and red indicate activation or inhibition
by Ang-(1–7)/Mas respectively. The green arrows indicate activation or positive effects, and the red lines indicate inhibition
of the process. (B) The main non-cardiovascular consequences of Ang-(1–7) on each process.
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insulin downstream effectors PI3K (phosphoinositide 3-kinase)
and AKT via the Mas receptor in HAECs [38,39], and IRS1 (in-
sulin receptor substrate 1) and JAK2 (Janus kinase 2) via the AT1R
in rat hearts [39]. Moreover, Ang-(1–7)/Mas negatively regulates
AngII/AT1R signalling in HAECs by promoting dephosphoryla-
tion of c-Src and ERK (extracellular-signal-regulated kinase)
1/2, and inhibition of NADPH oxidase activity [40]. Recently,
Mun˜oz and co-workers [41] used FFRs (fructose-fed rats), a
model of the metabolic syndrome, to study whether Ang-(1–7)
positively modulates insulin signalling via Mas and attenuates the
inhibitory effect of AngII on this signal transduction pathway. In-
deed, the authors observed that, in a Mas-dependent manner, the
downstream effectors of insulin including AKT, GSK-3β (glyco-
gen synthase kinase-3β) and AS160 (AKT substrate of 160 kDa)
were positively modulated by Ang-(1–7) in insulin-target tissues
(skeletal muscle, liver and adipose tissue). In the same way, the
inhibitory effect of AngII on these effectors was also attenuated
by Ang-(1–7) through Mas [41].
Western-blot-based studies have several advantages includ-
ing high sensitivity and specificity. However, one needs to rely on
commercially available specific antibodies with proven quality.
Moreover, this type of technique is hypothesis-driven. In other
words, the downstream effectors of a specific signalling cas-
cade need to have been defined previously. Therefore it is not
possible to identify unknown targets of signalling networks by
Western blotting. In order to overcome these technical limita-
tions and to gain more insights into the Mas signalling path-
way, we recently applied an MS-based approach to study the
HAEC phosphoproteome treated with Ang-(1–7) [42]. In that
study, we were able to detect 79 phosphoproteins that had
their phosphorylation state significantly changed over the ob-
served time frame (0–20 min). Among these phosphoproteins,
eight known downstream effectors of the insulin signal trans-
duction cascade had their phosphorylation levels differentially
regulated by Ang-(1–7): AKT1 (RAC-α serine/threonine pro-
tein kinase), PRAS40/AKT1S1 (proline-rich Akt substrate of
40 kDa/proline-rich AKT1 substrate 1), CAV1 (caveolin-1 iso-
form α), FOXO1 (forkhead box O1), MAPK1 (mitogen-activated
protein kinase 1)/ERK2, PXN (paxillin isoform 1), PI3KC2A
(class II PI3Kα) and VIM (vimentin) [42]. Ser124 on the AKT1
was phosphorylated after 3 min of Ang-(1–7) treatment. The
phosphorylation of this residue, together with the phosphoryla-
tion of Thr308 and Ser473, activates this kinase [43,44]. This find-
ing is in agreement with previous publications reporting that
AKT is rapidly activated by Ang-(1–7) [38,39,45]. The class I
PI3K plays an important role in the Ang-(1–7) signalling and
it is an upstream kinase that mediates AKT phosphorylation
in HAECs and rat hearts [38,39]. However, our phosphopro-
teome study revealed that PI3KC2A also plays a role in this
signal transduction cascade, as Mas activation induced the phos-
phorylation of Ser338 on this kinase [42]. Diverging from class I
PI3K, PI3KC2A is not an upstream kinase of the AKT signalling
branch [46,47]. Interestingly, this kinase induces translocation
of GLUT4 (glucose transporter 4) to the plasma membrane in
response to insulin stimulation [47]. PRAS40 regulates insulin-
induced mTOR (mammalian target of rapamycin) activity. When
Thr246 on PRAS40 is dephosphorylated, it binds to the mTOR
complex to inhibit it. On the other hand, AKT1 can phosphorylate
PRAS40 to induce its dissociation from mTOR, activating this
complex [48,49]. The transcriptional factor FOXO1 is another
component of the insulin signalling pathway that is a downstream
target of AKT1 [50]. Once activated, AKT1 translocates to the
nucleus and phosphorylates FOXO1 at Thr24, Ser256 and Ser319,
inactivating this transcriptional factor [50]. Strikingly, Ang-(1–7)
induced the dephosphorylation of Thr246 on PRAS40 and Ser256
on FOXO1. These data are consistent with mTOR inactivation
and FOXO1 activation. Indeed, we have also demonstrated that
Ang-(1–7) induces FOXO1 activation with its translocation to the
nucleus [42]. These findings suggest that Ang-(1–7) signalling is
a highly controlled system, possibly with more regulatory inputs
than previously suspected. Concerning the AKT/FOXO relation-
ship, the possibility that Ang-(1–7) modulates the equilibrium
between FOXO1 activation, which is predominant during the
fasting period, and AKT activation, which predominates after
feeding [51], should be explored in future studies (Figure 3).
Lipid metabolism is also regulated by Ang-(1–7) (Figure 2).
When treated with this heptapeptide, rats with diabetic cardio-
myopathy [32] and diabetic nephropathy [52] have a significant
reduction in dyslipidaemia in a Mas-dependent way (Figure 2b).
Moreover, Mas-knockout mice on the FVB/N background have
impaired lipid metabolism, leading to dyslipidaemia, lower gluc-
ose tolerance and insulin sensitivity, hyperinsulinaemia, hyper-
leptinaemia, lower adiponectin secretion, decreased glucose up-
take and increased abdominal fat mass when compared with the
wild-type phenotype [34]. On the other hand, TGR (transgenic)
animals with increased plasma levels of Ang-(1–7) had reduced
fat mass, decreased triacylglycerols (triglycerides) and choles-
terol levels, despite normal food intake [53]. In addition, the
expression levels of adiponectin and AP2 (adipose lipid-binding
protein 2) were increased, whereas there was a remarkable de-
crease in AGT expression in TGR animals. Adiponectin is a key
adipokine that regulates insulin sensitivity and tissue inflamma-
tion, and its plasma level is inversely proportional to body fat
content. AP2 is an important protein in the adipose tissue meta-
bolism involved in fatty acid esterification [53]. In the same way,
ACE-knockout mice had reduced fat mass due to an increase
in lipid metabolism and energy expenditure as a consequence
of higher expression levels of key genes involved in the hydro-
lysis of lipids into NEFAs (non-esterified ‘free’ fatty acids) [LPL
(lipoprotein lipase)], translocation of fatty acids to the mitochon-
dria [CPT-1 (carnitine palmitoyltransferase-1)], and β-oxidation
inside mitochondria and peroxisomes [LCAD (long-chain acyl-
CoA dehydrogenase)] [54].
Recently, two groups have shed more light on the molecular
mechanisms behind the beneficial modulation of lipid metabol-
ism by Ang-(1–7). Mario et al. [55] demonstrated that the expres-
sion of the PPARγ (peroxisome-proliferator-activated receptor
γ ) is compromised in Mas− / − mice (Figure 2A). The tran-
scription factor PPARγ is believed to have a beneficial effect in
insulin-resistant patients, as its activation leads to the expression
of target genes involved in fatty acid metabolism, triacylglycerol
storage and reduction in plasma NEFA supply [56,57]. In the same
way, Oh et al. [58] reported that Ang-(1–7) stimulates lipolysis via
Mas. Interestingly, these authors observed that an AKT inhibitor
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Figure 3 Putative mechanism by which Ang-(1–7) could modulate the balance of FOXO1/AKT in the fasting/feeding
cycle
In the fasting period, the inhibitory effect of AKT on FOXO1 is decreased as a consequence of the low insulin levels,
which leads to a reduction in the AKT phosphorylation (AKT-P) state. After feeding, insulin levels increase Akt phosphoryla-
tion, which then phosphorylates Ser256 on FOXO1 (FOXO-P), preventing its translocation to the nucleus. Ang-(1–7) could
amplify/modulate both phases due to its ability to induce the dephosphorylation of FOXO1 at Ser256, as well as AKT
phosphorylation via a PI3K-dependent pathway. Activation is represented in green and inhibition in red. AA, amino acids;
FA, fatty acid; PP, pentose pathway.
[API-2 (Akt/protein kinase B signalling inhibitor-2)] did not
attenuate Ang-(1–7)-induced lipolysis, whereas the inhibitor of
PI3K (wortmannin) and eNOS [endothelial NOS (NO synthase)]
[L-NAME (NG-nitro-L-arginine methyl ester)] significantly
reduced Ang-(1–7)-induced lipolysis. These findings suggest
that Ang-(1–7)-induced lipolysis is via a Mas/PI3K/eNOS
signalling pathway in an AKT-independent manner [58].
CELLULAR PROLIFERATION AND
ANGIOGENESIS
Studies in vivo and in vitro have suggested that Ang-(1–7) has
both anti-proliferative and anti-angiogenic properties, confer-
ring a potential alternative to cancer treatment (Figure 2B). The
growth of lung cancer cells, such as SK-LU-1, A549 and SK-
MES-1 cells, as well as human lung tumour xenografts, was
inhibited by treatment with Ang-(1–7) [59]. This phenotype was
explained, at least in part, as a consequence of the inhibition of
the ERK (MAPK) signal transduction pathway [59] or reduc-
tion in COX (cyclo-oxygenase)-2 [60] (Figure 2A), as both have
a central role in lung cancer cell proliferation. Treatment with
Ang-(1–7) also reduced the volume of orthotopic human breast
tumours, probably by decreasing the growth of cancer associ-
ated fibroblasts and fibrosis [61]. This later study also showed
an increase in the MAPK phosphatase DUSP1 (dual-specificity
phosphatase 1), reinforcing a possible role of Ang-(1–7) in the
reduction of MAPK/ERK signalling [61]. Indeed, our group has
recently shown that HAEC MAPK1 is dephosphorylated fol-
lowing Ang-(1–7) treatment, which probably leads to MAPK1
inactivation [42].
HDAC1 (histone deacetylase 1) is one of the proteins that has
a long-lasting inactivation through dephosphorylation of its reg-
ulatory sites (Ser421 and Ser423) after Ang-(1–7) treatment [42].
This protein is overexpressed in solid tumours and it has a role in
tumorigenesis and cancer progression. On the other hand, Ang-
(1–7) is also able to induce activation of the transcriptional factor
FOXO1 through dephosphorylation of its regulatory site (Ser256)
and consequently its translocation to the nucleus of endothe-
lial and tumour cells [42]. FOXO1 is responsible for triggering
the activation of genes involved in apoptosis, cell-cycle arrest and
oxidative stress resistance [62]. Recently, it is also been sugges-
ted that FOXO1 is a critical negative regulator of endothelial
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angiogenic behaviour [63], indicating a possible pathway by
which Ang-(1–7) can inhibit angiogenesis and, overall, tumori-
genesis. RASIP1 (Ras-interacting protein 1) also seems to be a
downstream effector of Ang-(1–7), as it was phosphorylated on
Ser331 after 3 min of Ang-(1–7) treatment [42]. RASIP1 acts in
blood vessel morphogenesis; however, it is yet to be established
whether this phosphorylation modulates the activity of this pro-
tein [64]. The role of Ang-(1–7) in angiogenesis inhibition was
shown in a mouse sponge model of angiogenesis [65]. Daily injec-
tions of Ang-(1–7) significantly inhibited angiogenesis, probably
through interaction with Mas, since its antagonist A779 blocked
this effect [65]. On the other hand, the AT1R and AT2R (type 2
AngII receptor) do not appear to be involved in this mechanism,
since their antagonists did not affect the Ang-(1–7) effect [65].
The mechanism of the anti-angiogenic effect of Ang-(1–7) in
mice is related to NO release [65]. Anton et al. [66] also showed
in vitro inhibition of angiogenesis by Ang-(1–7) in the tube form-
ation assay using endothelial cells. This inhibition was also ab-
olished by A779 [66]. Similarly, tube formation of A549 tumour
cells was also inhibited after Ang-(1–7) treatment [67]. A reduc-
tion in vessel density in Ang-(1–7)-treated human A549 lung tu-
mours was also observed. The mechanism of the anti-angiogenic
property of Ang-(1–7) in this condition seems to involve VEGF
(vascular endothelial growth factor)-A, a primary pro-angiogenic
protein, which was reduced after treatment with this heptapeptide
[67]. In addition, Ang-(1–7) decreased proliferation markers and
intratumoral vessel densities of a xenograft prostate tumour in
mice [68]. The treatment also reduced angiogenic factors such
VEGF and PlGF (placental growth factor), and increased the
soluble fraction of VEGF receptor 1 (sFlt-1), preventing the trig-
gering of the angiogenesis signalling pathway [68]. Data from
in vivo and in vitro studies are in line with the results obtained in
patients with advanced cancer that were treated with Ang-(1–7) in
Phase I clinical trials [69]. Patients treated with Ang-(1–7) had
reduced circulating levels of PIGF, a placental growth factor in-
volved in angiogenesis. In this trial, treatment with Ang-(1–7) led
to disease stabilization [69]. Finally, recent results have shown
that Ang-(1–7) treatment also has anti-metastatic properties in
lung and prostate cancer cells [70]. Ang-(1–7)-treated A549
human lung adenocarcinoma cells reduced the expression and
activity of the MMPs (metalloproteinases) MMP-2 and MMP-
9, which are involved in migration and invasion of cells. The
mechanism for this effect includes the inhibition of PI3K/AKT,
p38 and JNK (c-Jun N-terminal kianse) signalling pathways [71]
(Figure 2A). Therefore separate studies indicate that Ang-(1–7)
is a potential candidate for cancer treatment as it presents both
anti-proliferative and anti-angiogenic properties.
REPRODUCTION
Several tissues of the reproductive system express a local RAS.
Besides its vascular actions, the local RAS plays an important
role during spermatogenesis, follicle maturation and ovulation,
endometrium function and pregnancy [72–80] (Figure 2).
In female mammals, the ACE2/Ang-(1–7)/Mas axis has
been detected in the ovary, endometrium and placenta [72–76].
The ACE2/Ang-(1–7)/Mas axis is highly regulated by GnRH
(gonadotropin-releasing hormone) in the rat ovary [72]. This
hormone induces the expression of ACE2, leading to increased
levels of Ang-(1–7). Furthermore, GnRH positively regulates the
expression of Mas [72]. In the same way, the ACE2/Ang-(1–
7)/Mas axis also seems to play a role in the ovulation process
in cattle. Following 24 h of GnRH stimulation, Ang-(1–7) levels
increase in the follicular fluid, probably due to ACE2, NEP and
PEP up-regulation in granulosa cells [81]. In addition, Ang-(1–7)
increases during pro-oestrus and oestrus, and after eCG (equine
chorionic gonadotropin) treatment [76,82]. Furthermore, perfu-
sion of Ang-(1–7) in immature rat ovaries leads to increasing
progesterone and oestradiol synthesis in a Mas-dependent man-
ner [76]. The evidence for a role of the ACE2/Ang-(1–7)/Mas
axis in the female reproductive system was recently reinforced by
the observation that LH (luteinizing hormone) up-regulates the
ACE2/Ang-(1–7)/Mas axis and that Ang-(1–7) promotes mei-
otic resumption, possibly as a gonadotrophin intermediate [83].
Therefore there is substantial evidence suggesting an important
role for the ACE2/Ang-(1–7)/Mas axis in the ovulation process.
The ACE2/Ang-(1–7)/Mas axis is also found in the uterus. Al-
though the expression of ACE2 is constant during the menstrual
cycle, the levels of Ang-(1–7) and Mas in the glandular endomet-
rium increase during the mid- and late secretory phase [74]. This
local RAS may be regulated by sex steroids as increased expres-
sion of local renin following progesterone stimulation has been
reported previously [77]. Recently, Brosnihan et al. [84] reported
that Ang-(1–7) is present in the luminal and glandular epithelial
cells of pseudopregnant ovariectomized rats submitted to hor-
monal treatment. Ang-(1–7) levels were found to be reduced in
the decidualized horn when compared with the non-decidualized
horn, and was irregular in the luminal epithelium, although per-
sistent in the glandular epithelium [84]. In another study using
ovariectomized rats, Vaz-Silva et al. [85] also evaluated the tissue
distribution of Ang-(1–7) in the uterus, but compared hormone-
treated animals with non-treated ones. The authors observed that
Ang-(1–7) levels were significantly decreased in the glandular
epithelium and the circular myometrium of hormonally treated
animals, suggesting that Ang-(1–7) production is negatively mod-
ulated by steroids in the glandular compartment. It is important to
mention that Ang-(1–7) levels did not change in the luminal epi-
thelium, endometrial stroma and serosa following the hormonal
treatment [85]. In the same way, Mas expression did not change
in all uterine tissues of hormone-treated animals [85]. Neves
et al. [86] studied the uterine tissue distribution of Ang-(1–7) and
ACE2 during gestation in Sprague–Dawley rats. During early
pregnancy, Ang-(1–7) and ACE2 were found in the luminal and
glandular epithelial cells and in the primary and secondary de-
cidual zone, whereas, during late gestation, these RAS compon-
ents were detected in the labyrinth placenta and amniotic and
yolk sac epithelium [86].
The placenta has a pivotal role in the reproductive tract as it
allows nutrients uptake and waste elimination by the fetus via the
mother circulation, as well as gas exchange. The local RAS plays
an important role in the placentation, leading to angiogenesis and
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embryo development by modulating trophoblast proliferation and
invasion [75,79,80]. In the human placenta, ACE2 is markedly
up-regulated during early gestation (6–16 weeks) when compared
with term gestation (37–41 weeks), whereas ACE is differentially
expressed in the term placenta. Moreover, the localization of these
isoforms in the early gestation placentae is also divergent; while
ACE is only found in the fetal endothelium of the placental villi,
ACE2 is predominantly detected in the syncytiotrophoblast and
villous stroma [75]. Decreased Mas expression in the placenta has
been observed in pre-eclampsia, a condition in which the plasma
concentration of Ang-(1–7) is also lower than that present in
normotensive pregnant women [87,88].
The male human tract and the testis express all components of
the classical RAS [89,90]. Regarding the ACE2/Ang-(1–7)/Mas
axis, its components have been detected in the testis of rats [91],
mice [92], and humans [93]. In humans, Ang-(1–7) and Mas are
mainly found in the interstitial compartment and in the cytoplasm
of the Leydig cells, and are also detected with less intensity in
the seminiferous tubules [93]. As the Leydig cells are involved
in the synthesis of sex steroid hormones (e.g. testosterone), the
presence of Ang-(1–7) and Mas indicates that the ACE2/Ang-(1–
7)/Mas axis may modulate the production of testosterone by the
human testis. Even though it has been reported that Mas-deficient
mice remain fertile [94], Leal et al. [78] found that Mas− / − mice
exhibited a significant reduction in testis weight, although the
total number of Sertoli and Leydig cells were comparable in both
wild-type and knockout animals. Moreover, in Mas− / − anim-
als, the authors observed a significant number of apoptotic cells
during meiosis, giant cells and vacuoles in the seminiferous epi-
thelium, and a striking reduction in daily sperm production due
to disturbed spermatogenesis [78]. Accordingly, humans with
severe spermatogenesis impairment have lower levels of ACE2,
Ang-(1–7) and Mas when compared with fertile subjects [93].
Taken together, these data clearly indicate that the ACE2/Ang-
(1–7)/Mas axis modulates spermatogenesis.
FIBROSIS
Growing evidence suggests a protective role of Ang-(1–7) against
fibrosis. This pathological condition is characterized by the ex-
cessive deposition of extracellular matrix such as collagen, by
fibroblasts [95]. The proliferation of circulating fibrocytes, pre-
cursors of mature fibroblasts, is described to be involved in the
progression of tissue fibrosis and can be a predictor of myocar-
dial fibrosis [96]. Recently, a study showed that Ang-(1–7) causes
apoptosis of these cells, inhibits proliferation and diminishes
the secretion of collagen, leading to a regression of the car-
diac fibrosis [97]. Indeed, Ang-(1–7) protects against myocar-
dial fibrosis, counter-regulating the effects of AngII, as has been
shown by different studies reviewed recently by Oudit and Pen-
ninger [98]. Moreover, the deletion of its receptor Mas in mice
resulted in a pro-fibrotic profile of the extracellular matrix pro-
teins [99], whereas rhACE2 (recombinant human ACE2) admin-
istration inhibited the development of cardiac fibrosis, lowering
the levels of AngII and increasing Ang-(1–7) [100].
Besides its cardiac function, Ang-(1–7) can also reduce
fibrosis in different organs, such as lung, kidney and liver (Fig-
ure 2). Indeed, a study using an experimental model of liver
fibrosis, the BDL (bile-duct ligation) rat model, showed that Ang-
(1–7) administration improved different aspects of fibrosis, such
as reduction in collagen and hydroxyproline content and dimin-
ishment of gene expression of collagen IA1, α-SMA (smooth
muscle actin), VEGF and CTGF (connective tissue growth factor)
[101] (Figure 2A). A different study using the same model
demonstrated that incubation with the Mas antagonist A779 in-
creased the collagen deposition in the liver of BDL rats [102].
Other factors involved in fibrosis such as TGF (transforming
growth factor)-β1 and hydroxyproline were also enhanced after
A779 treatment [102]. In addition, genetic deletion of ACE2
worsened fibrosis in a chronic liver injury model, as demon-
strated by increased fibrosis markers such as collagen and TNF
(tumour necrosis factor)-α [103]. On the other hand, the admin-
istration of recombinant ACE2 attenuated fibrosis in mice [103].
In addition, data obtained in a rat fibrosis model showed elev-
ated ACE2 activity in chronically injured liver and consequently
enhanced Ang-(1–7) plasma levels [104,105]. In agreement, the
levels of circulating Ang-(1–7) are also increased in human liver
diseases, such as hepatitis C [104].
In order to demonstrate a possible action of Ang-(1–7) in
pulmonary fibrosis, studies used rats treated with bleomycin
to induce the development of fibrosis in the lung. Using this
model, it was demonstrated that overexpression of an Ang-(1–
7)-producing fusion protein or ACE2, using lentivirus-packaged
Ang-(1–7) administration into lungs of rats, decreased collagen
content and pro-inflammatory cytokines [106]. In addition, Mas
blockade with A779 abolished this effect, indicating that Mas me-
diates this action [106]. Furthermore, pre-incubation with Ang-
(1–7) prevents the AngII- or bleomycin-induced apoptosis of
alveolar epithelial cells, a distinct feature of pulmonary fibrosis,
as measured by caspase 3 and 9 activation and nuclear frag-
mentation [107]. The anti-apoptotic effect of Ang-(1–7) in these
cells involved inhibition of JNK phosphorylation [107] (Fig-
ure 2A). These observations suggest activation of the ACE2/Ang-
(1–7)/Mas axis as a potential strategy for antifibrotic therapy.
INFLAMMATION
The classical RAS component AngII via the AT1R contributes
to the inflammatory process, increasing the expression of pro-
inflammatory cytokines, chemokines and cell adhesion molecules
[108–111]. In contrast, recent studies have shown that Ang-(1–
7), through interaction with Mas, has an anti-inflammatory action
(Figure 2). Mouse peritoneal macrophages treated with Ang-(1–
7) had a reduction in pro-inflammatory cytokines expression, in-
cluding TNF-α and IL (interleukin)-6 after LPS (lipopolysacchar-
ide) stimulation [112] (Figure 2A). Indeed, the Mas transcripts
increased 8-fold after LPS exposure and the Mas antagonist A779
abrogated the anti-inflammatory effect, indicating that Mas medi-
ates the Ang-(1–7) anti-inflammatory effect in these cells [112].
The molecular mechanism of this effect involves c-Src, which is
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known to modulate inflammation, as it is dephosphorylated after
Ang-(1–7) treatment as shown by Western blot analysis [112].
Another study using two experimental models, AIA (antigen-
induced arthritis) in mice and AdIA (adjuvant-induced arthritis)
in rats, also showed an anti-inflammatory effect following Ang-
(1–7) treatment. Arthritic joints express Mas, and treatment with
Ang-(1–7) or the orally active Mas agonist AVE0991 ameliorates
arthritis in both experimental models [113]. Indeed, AIA-induced
neutrophil accumulation was reduced, as well as hypernocicep-
tion and the production of pro-inflammatory cytokines, such as
TNF-α and IL-1b, and the chemokine CXCL1 (CXC chemokine
ligand 1). Leucocyte rolling and adhesion were also reduced after
AVE0991 treatment. Moreover, the knockout of Mas in mice in-
creased different inflammatory features in arthritis, indicating
an endogenous property of Mas in modulating the inflammatory
process [113]. Thus Ang-(1–7) leads to an overall reduction in in-
flammation in models of arthritis, supporting a novel therapeutic
approach for arthritis [113].
Another inflammatory condition that has been reported to
be affected by Ang-(1–7) is atherosclerosis, which is charac-
terized by endothelial dysfunction, vascular inflammation and
the accumulation of lipids within the intima of the vessel wall
[114]. Chronic treatment with Ang-(1–7) of the atherosclerotic
model ApoE (apolipoprotein E)− / − knockout mice improved en-
dothelial function and attenuated the lesion progression as shown
by a reduction in fatty deposits (Oil Red O) and intima/media
ratio [115]. The same model treated with the Ang-(1–7) agon-
ist AVE 0991 also ameliorated atherogenesis. This is probably a
consequence of a decrease in inflammation as Ang-(1–7) inhib-
ited NADPH oxidase expression, which is involved in production
of ROS (reactive oxygen species), and diminished the express-
ion of co-stimulatory molecules on antigen-presenting cells, both
involved in inflammation development [116]. In addition, over-
expression of ACE2 reduced atherosclerosis in ApoE− / − mice,
with less macrophage infiltration and lipid deposition [117] and
stabilized the atherosclerotic plaques [118].
The effects of Ang-(1–7) have also recently been evaluated in
inflammatory conditions of the respiratory tract. A mouse model
of allergic asthma challenged with ovalbumin and treated with
Ang-(1–7) resulted in attenuation of ovalbumin-induced perivas-
cular and peribronchial inflammation and fibrosis [119]. One pos-
sible mechanism of the anti-inflammatory property of Ang-(1–7)
in the airways is through the ERK and NF-κB (nuclear factor κB)
signalling pathways, as Ang-(1–7) diminished the phosphoryla-
tion of ERK1 and IκBα (inhibitor of NF-κB) induced by ovalbu-
min [119] (Figure 2A). These effects are mediated by Mas, as its
antagonist A779 abolished the majority of these outcomes [119].
In addition, ACE2 and Ang-(1–7) levels were diminished after
intratracheal administration of LPS in rats, a model of ARDS
(acute respiratory distress syndrome) [120]. However, after treat-
ment with a protease-resistant form of Ang-(1–7), the lung injury
scores diminished and lung function was improved through atten-
uation of inflammation [120]. Thus these results indicate that the
local levels of Ang-(1–7) are crucial in avoiding the development
and progression of this syndrome [120].
Taken together, these studies have shown that Ang-(1–7) has
anti-inflammatory properties that can be useful in the treatment of
different inflammatory conditions such as arthritis, atherosclero-
sis and asthma. However, in the kidney, conflicting results have
been observed ([121]; reviewed in [122]).
CEREBROPROTECTION, LEARNING AND
MEMORY
Ang-(1–7) is the main angiotensin peptide in the CNS (central
nervous system) and is expressed in different regions of the brain,
including the hypothalamus, hippocampus, amygdala and many
others [123]. Besides its effects as a critical neuromodulator of
cardiac baroreflex mechanisms ([124]; reviewed in [125]), Ang-
(1–7) influences different non-cardiovascular functions in the
brain such as learning, memory and cerebroprotection against
ischaemia (Figure 2). Indeed, early in 1992, Holy et al. [126]
showed that administration of Ang-(1–7) had psychotropic ef-
fects.
The hippocampus is one of the regions with the highest ex-
pression of Ang-(1–7) [91]. The knockout or blockage of Mas
leads to a deficit in object recognition memory, indicating that
the Ang-(1–7)/Mas axis is an important modulator of learning
and memory [127]. One of the possible molecular pathways in-
volved in this mechanism is the synthesis of NO, a crucial factor
for object recognition memory that is modulated by Ang-(1–
7). Indeed, Yang et al. [128] have shown that Ang-(1–7), via
Mas activation, increases NO levels through nNOS (neuronal
NOS) in catecholaminergic neurons [128]. Besides that, Ang-(1–
7) through its interaction with Mas is also able to increase LTP
(long-term potentiation) in the hippocampus and amygdala [129].
LTP is the basis of learning and memory [129] (Figure 2B) and
it is increased by Ang-(1–7) in the amydgala through changes in
COX-2 and NO [130] (Figure 2A).
Ang-(1–7) may also confer protection against cerebral
ischaemic stroke. Central administration of Ang-(1–7) up-
regulates eNOS expression and consequently increases NO re-
lease in ischaemic tissues in rats [131]. Interestingly, ACE2 over-
expression also increased NOS (both eNOS and nNOS) and NO
levels in cerebrospinal fluid of mice [132]. During the early stages
of cerebral ischaemia, eNOS-derived NO is beneficial as it pro-
motes collateral circulation and microvascular flow [133]. How-
ever, the induction of iNOS (inducible NOS) expression in neur-
ons produces toxic levels of NO, contributing to neuronal death
elicited by cerebral ischaemia ([134]; reviewed in [135]). A recent
study using an endothelin-induced model of cerebral ischaemia
showed that central administration of Ang-(1–7) or an ACE2 ac-
tivator diminished the expression of iNOS (Figure 2B), leading
to a decrease in cerebral infarct size and behavioural deficits
(Figure 2A). Blockade of Mas with A779 reversed this pheno-
type [136]. Thus Ang-(1–7) appears to modulate the NO release
from different sources, contributing to improving the protection
against cerebral ischaemia. Another recent study added a new
mechanism for the cerebroprotective action of Ang-(1–7) [137].
Ang-(1–7) infusion into the cerebroventricular region attenuated
neurological deficits and diminished infarct volume. This effect
was mediated by its anti-inflammatory effects through a reduction
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of oxidative stress and pro-inflammatory cytokines, in addition to
NF-κB suppression [137] (Figure 2B). Therefore Ang-(1–7) is a
potential viable treatment to prevent individuals with a high risk
of stroke suffering greater damage caused by ischaemia. How-
ever, as pointed out by Jiang et al. [137], new studies are needed
to establish whether this peptide can improve cerebroprotection
in a post-ischaemia scenario.
ADDITIONAL MECHANISMS
Ang-(1–7) has been detected in glial cells of human retina [138]
and its receptor Mas has been described in different parts of the
eye, such as the retina and cilliary body, in rats [139]. Interest-
ingly, intravitreal treatment with Ang-(1–7) in rabbits diminished
the intraocular pressure without modifying aqueous humour out-
flow [140], indicating a possible direct action/function of this
peptide in the eye. In addition, intraocular administration of AAV
(adeno-associated virus)-mediated gene delivery of ACE2 or
Ang-(1–7) to diabetic rats and mice diminished diabetes-induced
retinal vascular leakage, infiltrating inflammatory cells and oxid-
ative damage, conferring protection against diabetic retinopathy
[141].
Ang-(1–7) also seems to be involved in several other pro-
cesses. For example, this heptapeptide increases the jejunal ab-
sorption of water when administered to rats. This effect occurs
through interaction with the Mas receptor and it is mediated by
NO and COX [142]. Ang-(1–7) also plays a role in the regulation
of haematopoiesis and progenitor cells, an action that was recently
reviewed by Durik et al. [143]. Baykan et al. [144] evaluated the
effects of Ang-(1–7) on skin ischaemia induced by subcutaneous
administration of nicotine in female Sprague–Dawley rats. The
authors observed that the group treated with Ang-(1–7) had a de-
crease in the ischaemic area due to increased angiogenesis [144].
Finally, Ang-(1–7) is highly expressed in the gastric mucosa and
this heptapeptide has a potent gastroprotective effect (reviewed
in [145]).
CONCLUSIONS AND PERSPECTIVES
As observed for AngII, the effects of Ang-(1–7) in the body are
not restricted to the cardiovascular or renal system. Although
it is difficult in many instances to differentiate between cardi-
ovascular and non-cardiovascular actions, it is clear that Ang-
(1–7) can influence many organs and systems. With advances
in our understanding related to its signalling mechanisms, novel
insights about the overall physiological and pathophysiological
role of Ang-(1–7) will soon be available. In general, despite
some controversial findings in the kidney [122], ACE2/Ang-(1–
7)/Mas seems to exert protective effects in several systems and
organs, opposing the detrimental effects of the overactivation of
the ACE/AngII/AT1R axis. What are the mechanisms govern-
ing the fine tuning of the equilibrium between these two RAS
axes? When and how do the angiotensin-mediated actions via the
AT2R take place in this balance? What is the role of Ang-(1–
9)-mediated effects in the overall function of the RAS [10,11]?
These are just a few questions waiting for enlightenment in order
to advance our knowledge of this fascinating system.
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